Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tomivosertib - Effector Therapeutics

Drug Profile

Tomivosertib - Effector Therapeutics

Alternative Names: eFT-508; Tomivosertib hydrochloride

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effector Therapeutics
  • Developer eFFECTOR Therapeutics; Medpace; Merck AG; Northwestern University; Pfizer
  • Class Antineoplastics; Cyclohexanes; Imidazoles; Immunotherapies; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Colorectal cancer; Diffuse large B cell lymphoma; Liver cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Phase I Acute myeloid leukaemia
  • No development reported Breast cancer

Most Recent Events

  • 24 Oct 2023 Preclinical trials in Acute myeloid leukaemia in USA (PO) before October 2023
  • 24 Oct 2023 eFFECTOR Therapeutics and Northwestern University agree to co-develop tomivosertib in USA for Acute myeloid leukemia
  • 24 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer released by eFFECTOR Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top